Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligands

Journal of Pharmacology and Experimental Therapeutics

Volumn 347, Issue 3, 2013, Pages 705-716

  Canal, Clinton E ^a   Cordova Sintjago, Tania ^a,b   Liu, Yue ^a   Kim, Myong S ^a   Morgan, Drake ^a,c   Booth, Raymond G ^a,b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYL 2 DIMETHYLAMINOTETRALIN DERIVATIVE; 6 HYDROXY 7 CHLORO 4 PHENYL 2 DIMETHYLAMINOTETRALIN; ALANINE; MUTANT PROTEIN; SERINE; SEROTONIN 2 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; EMBRYO; ENANTIOMER; HUMAN; HUMAN CELL; HYDROGEN BOND; MALE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; MOLECULAR PHARMACOLOGY; MOUSE; MUTAGENESIS; NONHUMAN; PHARMACOLOGY; POINT MUTATION; PRIORITY JOURNAL; RECEPTOR BINDING; SPECIES DIFFERENCE;

AMINO ACID SUBSTITUTION; AMPHETAMINES; ANIMALS; BEHAVIOR; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROLYSIS; LIGANDS; MALE; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; PHOSPHATIDYLINOSITOLS; POINT MUTATION; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN RECEPTOR AGONISTS; SPECIES SPECIFICITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDRONAPHTHALENES;

EID: 84887884469     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.208637     Document Type: Article

References (60)

1. Abbas A and Roth BL (2008) Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmac-other 9:3251-3259.
2. Almaula N, Ebersole BJ, Ballesteros J.A., Weinstein H., and Sealfon SC (1996a) Contribution of a helix 5 locus to selectivity of hallucinogenic and non-hallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxy-tryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus. Mol Pharmacol 50:34-42. (Pubitemid 26250072)
3. Almaula N, Ebersole BJ, Zhang D, Weinstein H., and Sealfon SC (1996b) Mapping the binding site pocket of the serotonin 5-hydroxytryptamine2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin. J Biol Chem 271: 14672-14675.
4. Armbruster BN, Li X, Pausch M.H., Herlitze S., and Roth BL (2007) Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci USA 104:5163-5168. (Pubitemid 47186193)
5. Ballesteros JA, Jensen AD, Liapakis G, Rasmussen S.G., Shi L., Gether U, and Javitch JA (2001) Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 276:29171-29177.
6. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors, in Receptor Molecular Biology (Sealfon SC ed) pp 366-428, Academic Press, San Diego, CA.
7. Booth RG, Fang L, Huang Y., Wilczynski A, and Sivendran S (2009) (1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity. Eur J Pharmacol 615:1-9.
8. Braden MR and Nichols DE (2007) Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor. Mol Pharmacol 72:1200-1209. (Pubitemid 350012594)
9. Bucholtz EC, Brown RL, Tropsha A, Booth R.G., and Wyrick SD (1999) Synthesis, evaluation, and comparative molecular field analysis of 1-phenyl-3-amino-1, 2, 3, 4-tetrahydronaphthalenes as ligands for histamine H(1) receptors. J Med Chem 42: 3041-3054. (Pubitemid 29384039)
10. Canal CE, Booth RG, and Morgan D (2013) Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2, 5-dimethoxy-4-iodoamphetamine elicited head-twitch response model. Neuropharmacology 70:112-121.
11. Canal CE, Cordova-Sintjago TC, Villa N.Y., Fang LJ, and Booth RG (2011) Drug discovery targeting human 5-HT(2C) receptors: residues S3.36 and Y7.43 impact ligand-binding pocket structure via hydrogen bond formation. Eur J Pharmacol 673:1-12.
12. Canal CE and Morgan D (2012) Head-twitch response in rodents induced by the hallucinogen 2, 5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model. Drug Test Anal 4: 556-576.
13. Canal CE, Olaghere da Silva UB, Gresch PJ, Watt EE, Sanders-Bush E, and Airey DC (2010) The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen. Psychopharmacology (Berl) 209:163-174.
14. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
15. Clark M, Cramer RD, III, and van Opdenhosch N (1989) Validation of the general purpose Tripos 5.2 force field. J Comput Chem 10:982-1012.
16. Córdova-Sintjago T., Sakhuja R, Kondabolu K., Canal CE, and Booth RG (2012a) Molecular determinants for ligand binding at serotonin 5-HT2A and 5-HT2C GPCRs: experimental affinity results analyzed by molecular modeling and ligand docking studies. Int J Quantum Chem 112:3807-3814.
17. Córdova-Sintjago T., Villa N, Canal C., and Booth R (2012b) Human serotonin 5-HT2C G protein-coupled receptor homology model from the beta(2) adrenoceptor structure: ligand docking and mutagenesis studies. Int J Quantum Chem 112: 140-149.
18. Cordova-Sintjago T.C., Fang L, Bruysters M., Leurs R, and Booth RG (2012c) Molecular determinants of ligand binding at the human histamine H1 receptor: site-directed mutagenesis results analyzed with ligand docking and molecular dynamics studies at H1 homology and crystal structure models. J Chem Pharm Res 4: 2937-2951.
19. Cornell WD, Cieplak P, Bayly C.I., Gould IR, Merz KM, Ferguson DM, Spellmeyer D.C., Fox T., Caldwell JW, and Kollman PA (1995) A second-generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 117: 5179-5197.
20. Cummings DF, Ericksen SS, Goetz A, and Schetz JA (2010) Transmembrane segment five serines of the D4 dopamine receptor uniquely influence the interactions of dopamine, norepinephrine, and Ro10-4548. J Pharmacol Exp Ther 333: 682-695.
21. Cunningham KA, Anastasio NC, Fox R.G., Stutz SJ, Bubar MJ, Swinford SE, Watson C.S., Gilbertson SR, Rice KC, and Rosenzweig-Lipson S, et al (2013) Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction. ACS Chem Neurosci 4: 110-121.
22. Darmani NA (1993) Role of the inhibitory adrenergic alpha 2 and serotonergic 5-HT1A components of cocaine's actions on the DOI-induced head-twitch response in 5-HT2-receptor supersensitive mice. Pharmacol Biochem Behav 45: 269-274.
23. Dougherty JP and Aloyo VJ (2011) Pharmacological and behavioral characterization of the 5-HT2A receptor in C57BL/6N mice. Psychopharmacology (Berl) 215: 581-593.
24. Dracheva S, Patel N, Woo D.A., Marcus SM, Siever LJ, and Haroutunian V (2008) Increased serotonin 2C receptor mRNA editing: a possible risk factor for suicide. Mol Psychiatry 13:1001-1010.
25. Ebersole BJ, Visiers I, Weinstein H., and Sealfon SC (2003) Molecular basis of partial agonism: orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy. Mol Pharmacol 63:36-43. (Pubitemid 36043806)
26. Egan CT, Herrick-Davis K, Miller K., Glennon RA, and Teitler M (1998) Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors. Psychopharmacology (Berl) 136:409-414. (Pubitemid 28189672)
27. Gasteiger J and Marsili M (1980) Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges. Tetrahedron 36:3219-3228.
28. Glennon RA (1992) Animal models for assessing classical hallucinogens, in Animal Models for the Assessment of Psychoactive Drugs (Boulton AA, Baker GB, and Wu PH eds) pp 345-381, Humana Press, Clifton, NJ.
29. Halberstadt AL and Geyer MA (2013) Effects of the hallucinogen 2, 5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology pii: S0028-3908(13)00392-4. doi:10.1016/j. neuropharm.2013.08.025.
30. Heller H, Schaefer M, and Schulten K (1993) Molecular dynamics simulation of a bilayer of 200 lipids in the gel and in the liquid crystal phases. J Phys Chem 97: 8343-8360.
31. Higgins GA, Sellers EM, and Fletcher PJ (2013) From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists. Trends Pharmacol Sci pii: S0165-6147(13)00150-8. doi:10.1016/j.tips.2013.08.001.
32. Istyastono EP, Nijmeijer S, Lim H.D., van de Stolpe A, Roumen L, Kooistra AJ, Vischer HF, de Esch IJ, Leurs R, and de Graaf C (2011) Molecular determinants of ligand binding modes in the histamine H(4) receptor: linking ligand-based three-dimensional quantitative structure-activity relationship (3D-QSAR) models to in silico guided receptor mutagenesis studies. J Med Chem 54:8136-8147.
33. Jensen AA, Plath N, Pedersen M.H., Isberg V., Krall J, Wellendorph P, Stensbøl TB, Gloriam D.E., Krogsgaard-Larsen P, and Frølund B (2013) Design, synthesis, and pharmacological characterization of N- and O-substituted 5, 6, 7, 8-tetrahydro-4H-isoxazolo[4, 5-d]azepin-3-ol analogues: novel 5-HT(2A)/5-HT(2C) receptor agonists with pro-cognitive properties. J Med Chem 56:1211-1227.
34. Johnson MP, Loncharich RJ, Baez M, and Nelson DL (1994) Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol Pharmacol 45:277-286. (Pubitemid 24063081)
35. Kao HT, Adham N, Olsen M.A., Weinshank RL, Branchek TA, and Hartig PR (1992) Site-directed mutagenesis of a single residue changes the binding properties of the serotonin 5-HT2 receptor from a human to a rat pharmacology. FEBS Lett 307: 324-328.
36. Kristiansen K, Kroeze WK, Willins D.L., Gelber EI, Savage JE, Glennon RA, and Roth BL (2000) A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism. J Pharmacol Exp Ther 293:735-746.
37. Larkin MA, Blackshields G, Brown N.P., Chenna R., McGettigan PA, McWilliam H, Valentin F, Wallace I.M., Wilm A., and Lopez R, et al (2007) Clustal W and Clustal X version 2.0. Bioinformatics 23:2947-2948. (Pubitemid 350162903)
38. Marek GJ and Aghajanian GK (1996) LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex. J Pharmacol Exp Ther 278:1373-1382.
39. Miller KJ, Wu GY, Varnes J.G., Levesque P., Li J, Li D, Robl J.A., Rossi KA, and Wacker DA (2009) Position 5.46 of the serotonin 5-HT2A receptor contributes to a species-dependent variation for the 5-HT2C agonist (R)-9-ethyl-1, 3, 4, 10b-tetrahydro-7-trifluoromethylpyrazino[2, 1-a]isoindol-6(2H)-one: impact on selectivity and toxi-cological evaluation. Mol Pharmacol 76:1211-1219.
40. Morgan D, Kondabolu K, Kuipers A., Sakhuja R, Robertson KL, Rowland N.E., and Booth RG (2013) Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications. Neuropharmacology 72:274-281.
41. Nelson DL, Lucaites VL, Audia J.E., Nissen JS, and Wainscott DB (1993) Species differences in the pharmacology of the 5-hydroxytryptamine2 receptor: structurally specific differentiation by ergolines and tryptamines. J Pharmacol Exp Ther 265: 1272-1279. (Pubitemid 23321030)
42. Nichols CD (2009) Serotonin 5-HT(2A) receptor function as a contributing factor to both neuropsychiatric and cardiovascular diseases. Cardiovasc Psychiatry Neurol 2009:475108.
43. Porter RH, Benwell KR, Lamb H, Malcolm C.S., Allen NH, Revell DF, Adams DR, and Sheardown MJ (1999) Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br J Pharmacol 128:13-20. (Pubitemid 29425262)
44. Ray TS (2010) Psychedelics and the human receptorome. PLoS ONE 5:e9019.
45. Rowland NE, Crump EM, Nguyen N, Robertson K., Sun Z, and Booth RG (2008) Effect of (-)-trans-PAT, a novel 5-HT2C receptor agonist, on intake of palatable food in mice. Pharmacol Biochem Behav 91:176-180.
46. Sewell RA, Halpern JH, and Pope HG, Jr (2006) Response of cluster headache to psilocybin and LSD. Neurology 66:1920-1922. (Pubitemid 44049828)
47. Shan J, Khelashvili G, Mondal S., Mehler EL, and Weinstein H (2012) Ligand-dependent conformations and dynamics of the serotonin 5-HT(2A) receptor determine its activation and membrane-driven oligomerization properties. PLOS Comput Biol 8:e1002473.
48. Shapiro DA, Kristiansen K, Kroeze W.K., and Roth BL (2000) Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Mol Pharmacol 58:877-886.
49. Smith SR, Weissman NJ, Anderson C.M., Sanchez M., Chuang E, Stubbe S, Bays H., and Shanahan WR; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group (2010) Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 363: 245-256.
50. Strader CD, Candelore MR, Hill W.S., Sigal IS, and Dixon RA (1989) Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. J Biol Chem 264:13572-13578. (Pubitemid 19198437)
51. Sun J, Kuo PH, Riley B.P., Kendler KS, and Zhao Z (2008) Candidate genes for schizophrenia: a survey of association studies and gene ranking. Am J Med Genet B Neuropsychiatr Genet 147B:1173-1181.
52. Suratman S, Leach K, Sexton P., Felder C, Loiacono R, and Christopoulos A (2011) Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. Br J Pharmacol 162:1659-1670.
53. Thanseem I, Anitha A, Nakamura K., Suda S, Iwata K, Matsuzaki H., Ohtsubo M, Ueki T, Katayama T., and Iwata Y, et al. (2012) Elevated transcription factor specificity protein 1 in autistic brains alters the expression of autism candidate genes. Biol Psychiatry 71:410-418.
54. Thompson JD, Higgins DG, and Gibson TJ (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673-4680. (Pubitemid 24354800)
55. van Rhee AM and Jacobson KA (1996) Molecular architecture of G protein-coupled receptors. Drug Dev Res 37:1-38. (Pubitemid 26106319)
56. Vincek AS and Booth RG (2009) New approach to 4-phenyl-/3-aminotetralin from 4-(3-halophenyl)tetralen-2-ol phenylacetate. Tetrahedron Lett 50:5107-5109.
57. Wainscott DB, Lucaites VL, Kursar J.D., Baez M., and Nelson DL (1996) Pharmaco-logic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences. J Pharmacol Exp Ther 276:720-727.
58. Wang C, Jiang Y, Ma J.M., Wu HX, Wacker D, Katritch V, Han G.W., Liu W., Huang XP, and Vardy E, et al (2013) Structural basis for molecular recognition at serotonin receptors. Science 340:610-614.
59. Warne T and Tate CG (2013) The importance of interactions with helix 5 in determining the efficacy of β-adrenoceptor ligands. Biochem Soc Trans 41: 159-165.
60. Weinstein H (2005) Hallucinogen actions on 5-HT receptors reveal distinct mechanisms of activation and signaling by G protein-coupled receptors. AAPS J 7: E871-E884.